



## Antibody against Viral Infection: Advances in the Era of Therapeutic Monoclonal Antibody

Guest Editor:

### Dr. Laurent Dacheux

Institut Pasteur, National Reference Centre for Rabies, WHO Collaborating Center for Reference and Research on Rabies, Lyssavirus Epidemiology and Neuropathology Unit, 75724 Paris, France

Deadline for manuscript submissions:

**closed (31 July 2021)**

### Message from the Guest Editor

Dear Colleagues,

Antibodies are one of the key components of the immune system to control viral infections. The control by this armed component of the humoral immunity is dual, based on direct interference with the viral replication process (mainly through a neutralization effect on virions) or by targeting infected cells to immune effector cells. The recent advent of the era of monoclonal antibodies, made possible by hybridoma technology, has opened new avenues in the field of therapeutics for viral disease.

This Special Issue of Vaccines is open to original reports, perspectives, reviews, or research articles focusing on recent advances on the use of antibodies against viral infection. The submission of articles covering the following research areas is especially encouraged:

- Experimental development, characterization, or clinical evaluation of novel or existing antiviral antibodies;
- Mechanisms of antiviral activities of antibodies;
- Development of vaccine strategies to elicit antiviral antibodies.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)